1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
610E9096AED5994BE85257F3800765224
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-resourcing-successful-product-launch-activity-investments?opendocument
18
19opendocument
2044.200.122.214
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Product Launch Excellence

Resourcing a Successful Product Launch: Activity Investments

ID: 5397


Features:

7 Info Graphics

27 Data Graphics

1000+ Metrics


Pages/Slides: 39


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Resourcing a Successful Product Launch: Activity Investments"

STUDY OVERVIEW

The launch paradigm for new pharmaceutical products has evolved considerably over the past decade. To gain a foothold in the highly competitive marketplace, launch leaders can no longer rely on past experiences when budgeting for key product launch activities.

To assist biopharma leaders in developing competitive launch and pre-launch activity budgets, Best Practices, LLC undertook benchmarking research that examined the cost of key launch activities for launch year and the three years preceding launch.

In particular, the study benchmarks the average cost for 12 key marketing, education and market access activities for a new pharmaceutical product launch, by launch year and product type. Launch leaders can use this study to compare their budgets for key launch activities with current industry benchmarks.

Data in this study is presented for the following segments: drug type, launch year, market entry position, peak annual revenue projection, targeted physicians and therapeutic area.


KEY TOPICS

  • Launch Activity Investment Benchmarks

SAMPLE KEY METRICS
  • Total U.S. investment for pre-launch activities in four different budget years: Launch Year, Year -1, Year -2, and Year -3. Budget numbers include all resources invested in promotional, educational & market-access activities, excluding only clinical trial costs.
  • Investment for products with projected peak revenue of $1 billion or less for the launch year and the three years preceding launch.
  • Investment for products with projected peak revenue of more than $1 billion for the launch year and the three years preceding launch.


SAMPLE KEY FINDINGS
  • On average, study participants spend the most on Agency Fees (excluding DTC) during launch year.
  • For differentiated products entering an already established market, physician education receives the highest investment for launch year as well as one year preceding launch.

METHODOLOGY

This research engaged 34 marketing & commercial leaders from 27 leading pharmaceutical, biotech, and life sciences companies. Eleven study participants represent large pharma organizations, while the remaining benchmark class represent medium or small companies.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Medical Device; Manufacturing; Biotech; Consumer Products; Chemical


Companies Profiled:
Abbott; Cutanea Life Sciences; Abbvie; Pharmacyclics; Astellas; Sebela; Baxter Healthcare; Bayer; Boehringer Ingelheim; EMD Serono; Nektar Therapeutics; Grunenthal; Inspire Pharmaceuticals; Lundbeck; GlaxoSmithKline ; Novartis; Noven Therapeuticals; Novo Nordisk; Regeneron; Roche; Servier; Shire; Teva Pharmaceutical Industries Ltd; Zydus Cadila; Genentech; Lilly

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.